Meeting Buffer Demand
Overcoming the challenges of traditional buffer preparation and a revolution in buffer management has arrived : Allegro™ Buffer Management System Launch Event.
The changing face of the biopharmaceutical industry has brought about an increased need for flexibility and adaptability, with developments in upstream processing resulting in higher product yields, and with multi-product facilities becoming commonplace. In addition to this there is always the ever-present call for manufacturers to reduce costs without compromising the essential facets of quality and safety.
Process intensification, specifically higher cell culture titers, has increased the volume of buffer required and magnified the challenges posed by traditional buffer preparation. The extensive and varied range of biotherapeutics currently being developed has led to significantly different process demands, and the necessity for biomanufacturing facilities to cope with processes that may be vastly different in scale. This has a direct impact on the number of process buffers required.
The good news is that the pain points associated with buffer preparation can now be addressed efficiently through the advancement of well-designed automated technologies. Our understanding of the bottlenecks in buffer management that hinder production, enables us to partner with you to attain a robust buffer management strategy that encompasses preparation, mixing, storage, and a just-in-time solution at the point of use.
And you will learn :
- The current pain points associated with buffer preparation
- What are the current and future market trends
- What Pall is doing to address these concerns
- About the new Allegro Connect buffer management system
Why the introduction of X-ray sterilization technology is a critical change for single-use industry, and how gamma and X-ray irradiation compare
The market demand for gamma irradiation, the current primary method for the sterilization in SUT, will soon significantly exceed supply, creating an urgent need for alternatives.
Join Christelle Marcoux from GSK Vaccines (BioPhorum workstream member on alternatives to gamma sterilization) and James Hathcock, PhD of Pall Corporation (Bio-Process Systems Alliance X-Ray Committee Co-Chair) as they discuss the introduction of X-ray sterilization technology.
You will learn more about:
- Why this is a critical change for industry and the responsibilities of each stakeholder
- Key questions to address for biomanufacturers
- How gamma and X-ray irradiation compare
- What testing has been completed and key milestones for readiness for industry
- An example of how to qualify a SUS sterilized with X-ray irradiation